Literature DB >> 20170884

Procedural and mid-term results in patients with aortic stenosis treated with implantation of 2 (in-series) CoreValve prostheses in 1 procedure.

Ulrich Gerckens1, George Latsios, Ralf Mueller, Lutz Buellesfeld, Daniel John, Seyrani Yuecel, Barthel Sauren, Thomas Felderhof, Stein Iversen, Eberhard Grube.   

Abstract

OBJECTIVES: This study sought to assess post-procedural and mid-term outcome of patients, in which a second "in-series" CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) was implanted during the same procedure.
BACKGROUND: Because of the increasing number of patients implanted with CoreValves, the need for management of special complications has emerged. A misplaced prosthesis can be corrected by various maneuvers. An option is to pull the valve out of the aortic annulus into the ascending aorta or beyond and position a second one (in series).
METHODS: Out of 277 patients who underwent CoreValve implantation with the 18-F device in our institution, we had to implant a second prosthesis (due to severe aortic regurgitation or dislocation of the first one) in 9 (3.2%). Immediate post-procedural as well as mid-term follow-up data (5 to 20 months, mean 10.6 +/- 6 months, total 95 patient-months) were collected for analysis.
RESULTS: All implantations of the second device were successful, resulting in elimination of the gradient (mean gradient 43.1+/-4.0 mm Hg before to 7.0 +/- 1.1 mm Hg after implantation). There was no final aortic regurgitation grade >or=2+. The extra-anatomically placed first prosthesis (ascending aorta, n = 8; abdominal aorta, n = 1) did not cause any clinical sequelae or gradients. During mid-term follow-up, none of the 18 prostheses showed any sign of malfunction. Specifically, there were no signs of valve migration or of worsening paravalvular regurgitation. No case of valve thrombosis was documented.
CONCLUSIONS: A second CoreValve can be safely and effectively implanted in an in-series manner, without periprocedural complications. No problems arose on mid-term follow-up, ranging up to 20 months. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20170884     DOI: 10.1016/j.jcin.2009.11.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  2 in total

1.  Lotus-in-Evolut R transcatheter aortic valve implantation for severe paravalvular leak.

Authors:  Shabnam Rashid; Daniel J Blackman; Christopher Malkin
Journal:  J Cardiol Cases       Date:  2016-06-09

2.  Anatomical Predictors of Valve Malposition During Self-Expandable Transcatheter Aortic Valve Replacement.

Authors:  Jie Li; Yinghao Sun; Shengneng Zheng; Guang Li; Haojian Dong; Ming Fu; Yujing Mo; Yi Li; Huadong Liu; Zhaoyan Xu; Liting Zhang; Yong Cao; Ruixin Fan; D Scott Lim; Jianfang Luo
Journal:  Front Cardiovasc Med       Date:  2021-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.